secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001193125-26-204147
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Q1 2026: net loss narrows to $122.9M; CASGEVY revenue $43M; cash at $2.44B
--------------------------------------------------------------------------------

- Net loss of $122.9M vs $136.0M in Q1 2025; R&D spend $68.6M, G&A $17.2M.
- CASGEVY revenue of $43M; collaboration expense net $45.9M, down on higher revenue share.
- Cash, equivalents and securities $2,441.8M, up from $1,975.8M, boosted by $585.4M convertible note.
- Zugo-cel started 3rd Phase 1 in autoimmune neurology; SLE patients remain in DORIS remission at Month 12 and Month 6.
- In vivo CTX310 IND cleared for US; CTX460 (AATD) and CTX340 (hypertension) on track for mid-2026 and H1 2026 clinical starts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000119312526204147/0001193125-26-204147-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000119312526204147/crsp-20260504.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-204147

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer